All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Treatment sequencing for anemic myelofibrosis
with Jean-Jacques Kiladjian & Angela Fleischman
Monday, February 26, 2024 | 16:30 CET
This independent educational activity is supported by Bristol Myers Squibb. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
Bookmark this article
On January 25, 2022, it was announced that the phase III, pivotal MOMENTUM (NCT04173494) study, evaluating momelotinib for the treatment of patients with symptomatic myelofibrosis (MF), achieved both its primary and major secondary endpoints; momelotinib has been associated with statistically significant improvements in symptoms, spleen size, and anemia.
Momelotinib is an orally available inhibitor of Janus kinase 1 and 2 (JAK1/2) and activin A receptor type I/activin receptor-like kinase-2 (ALK-2). The agent is currently being evaluated across a number of clinical trials for the treatment of patients with MF who have received prior treatment with a U.S. Food and Drug administration (FDA)-approved JAK inhibitor.
MOMENTUM is a phase III, double-blind, randomized study investigating momelotinib versus danazol in patients aged ≥18 years with MF who meet the following eligibility criteria:
Across 21 countries, 195 patients were enrolled and randomized 2:1 to momelotinib (n = 130) and danazol (n = 65) treatment arms. Patients receiving danazol were able to transfer to momelotinib after 24 weeks of treatment, or earlier in the instance of splenic progression.
The study used the following endpoints to establish the value of momelotinib in MF:
Topline data from the MOMENTUM study demonstrate the encouraging efficacy and safety profiles of momelotinib versus danazol for patients with MF (Figure 1).
Figure 1. A Efficacy and B safety outcomes observed in patients enrolled in the MOMENTUM study*
AEs, adverse events; SRR, splenic response rate; TEAEs, treatment-emergent adverse events; TI, transfusion independence; TSS, Total Symptom Score.
*Data from BusinessWire1
Findings from the MOMENTUM study suggest that momelotinib represents a promising treatment approach to MF with anemia, or patients with MF who may progress to symptomatic anemia.
MOMENTUM: How might momelotinib change the treatment for cytopenic patients with MF?
During the ASCO 2022 Annual Meeting, the MPN Hub was pleased to speak to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, How might momelotinib change...
Editorial theme | The management of relapsed/refractory myelofibrosis: Part 2 – novel JAK inhibitors
As part of the new editorial theme on the management of relapsed or refractory myelofibrosis (R/R MF), we are now looking at the emerging therapeutic...
Subscribe to get the best content related to MPN delivered to your inbox